Advanced Practice Providers

View More Breast Cancer Gastrointestinal Cancer Genetics Genitourinary Cancer Gynecologic Cancer Hematology Immuno-Oncology Lung Cancer Nurse Navigation Prevention Supportive Care

Breast Cancer Gastrointestinal Cancer Genetics Genitourinary Cancer Gynecologic Cancer Hematology Immuno-Oncology Lung Cancer Nurse Navigation Prevention Supportive Care

Oncology Drug Crash Course

Medical World News

Insights Medical World News Peer Exchange Podcasts Videos

Conference Coverage

Conference Listing

Cancer Insight Summary Slides

Continuing Education

Cancer Insight Summary Slides Continuing Education

Subscribe Partners

CancerNetwork.com
CureToday.com
OncLive.com
TargetedOnc.com
Privacy
Terms & Conditions
Do Not Sell My Information

© 2023 MJH Life Sciences and Oncology Nursing News. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advertisement

Specialty

Advanced Practice Providers

ClinicalSee All >

Breast Cancer
Gastrointestinal Cancer
Genetics
Genitourinary Cancer
Gynecologic Cancer
Hematology
Immuno-Oncology
Lung Cancer
Nurse Navigation
Prevention
Supportive Care

CancerNetwork.com
CureToday.com
OncLive.com
TargetedOnc.com
Privacy
Terms & Conditions
Do Not Sell My Information

© 2023 MJH Life Sciences^™ and Oncology Nursing News. All rights reserved.

Metastatic CRC Nursing Webinar

January 8, 2021

Related Content:

VideosGastrointestinal Cancer

Neoadjuvant Treatment Crosses Cost-Effective Threshold Vs Upfront Surgery in Pancreatic Cancer

Neoadjuvant Treatment Crosses Cost-Effective Threshold Vs Upfront Surgery in Pancreatic Cancer

$Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer$

Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer

Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma

Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma

Advertisement

Advertisement